Processing

Please wait...

Settings

Settings

Goto Application

1. EP2831108 - IMMUNOMODULATING CYCLIC COMPOUNDS FROM THE BC LOOP OF HUMAN PD1

Office
European Patent Office
Application Number 13720539
Application Date 28.03.2013
Publication Number 2831108
Publication Date 04.02.2015
Publication Kind A1
IPC
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
CPC
A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 38/1774
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
C07K 14/4747
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
4701not used
4747Apoptosis related proteins
C07K 14/70521
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
70521CD28, CD152
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applicants AURIGENE DISCOVERY TECH LTD
Inventors SASIKUMAR POTTAYIL GOVINDAN NAIR
RAMACHANDRA MURALIDHARA
Designated States
Priority Data 1213CH2012 29.03.2012 IN
Title
(DE) CYCLISCHE IMMUNMODULIERENDE VERBINDUNGEN AUS DER BC-SCHLEIFE VON MENSCHLICHEM PD1
(EN) IMMUNOMODULATING CYCLIC COMPOUNDS FROM THE BC LOOP OF HUMAN PD1
(FR) COMPOSÉS CYCLIQUES D'IMMUNOMODULATION PROVENANT DE LA BOUCLE BC DE PD1 HUMAIN
Abstract
(EN) The present invention relates to novel cyclic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivative's of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
(FR) La présente invention concerne de nouveaux composés cycliques en tant qu'agents thérapeutiques aptes à inhiber la voie de signalisation de la mort cellulaire programmée 1 (PD1). L'invention concerne également des dérivés des agents thérapeutiques. L'invention englobe également l'utilisation desdits agents thérapeutiques et dérivés pour le traitement de troubles par l'intermédiaire d'immunopotentialisation comprenant l'inhibition d'un signal immunosuppresseur induit en raison de PD-1, PD-L1 ou PD-L2, et des thérapies à l'aide de ceux-ci.